Literature DB >> 28718439

Super-Enhancer-Driven Transcriptional Dependencies in Cancer.

Satyaki Sengupta1, Rani E George2.   

Abstract

Transcriptional deregulation is one of the core tenets of cancer biology and is underpinned by alterations in both protein-coding genes and noncoding regulatory elements. Large regulatory elements, so-called super-enhancers (SEs), are central to the maintenance of cancer cell identity and promote oncogenic transcription to which cancer cells become highly addicted. Such dependence on SE-driven transcription for proliferation and survival offers an Achilles heel for the therapeutic targeting of cancer cells. Indeed, inhibition of the cellular machinery required for the assembly and maintenance of SEs dampens oncogenic transcription and inhibits tumor growth. In this article, we review the organization, function, and regulation of oncogenic SEs and their contribution to the cancer cell state.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28718439      PMCID: PMC5546010          DOI: 10.1016/j.trecan.2017.03.006

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  88 in total

1.  Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

Authors:  Marc R Mansour; Brian J Abraham; Lars Anders; Alla Berezovskaya; Alejandro Gutierrez; Adam D Durbin; Julia Etchin; Lee Lawton; Stephen E Sallan; Lewis B Silverman; Mignon L Loh; Stephen P Hunger; Takaomi Sanda; Richard A Young; A Thomas Look
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

2.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.

Authors:  Giorgio G Galli; Matteo Carrara; Wei-Chien Yuan; Christian Valdes-Quezada; Basanta Gurung; Brian Pepe-Mooney; Tinghu Zhang; Geert Geeven; Nathanael S Gray; Wouter de Laat; Raffaele A Calogero; Fernando D Camargo
Journal:  Mol Cell       Date:  2015-10-01       Impact factor: 17.970

4.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Authors:  Camilla L Christensen; Nicholas Kwiatkowski; Brian J Abraham; Julian Carretero; Fatima Al-Shahrour; Tinghu Zhang; Edmond Chipumuro; Grit S Herter-Sprie; Esra A Akbay; Abigail Altabef; Jianming Zhang; Takeshi Shimamura; Marzia Capelletti; Jakob B Reibel; Jillian D Cavanaugh; Peng Gao; Yan Liu; Signe R Michaelsen; Hans S Poulsen; Amir R Aref; David A Barbie; James E Bradner; Rani E George; Nathanael S Gray; Richard A Young; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

5.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

Review 6.  Enhancer malfunction in cancer.

Authors:  Hans-Martin Herz; Deqing Hu; Ali Shilatifard
Journal:  Mol Cell       Date:  2014-03-20       Impact factor: 17.970

Review 7.  Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer.

Authors:  Dean Yimlamai; Brendan H Fowl; Fernando D Camargo
Journal:  J Hepatol       Date:  2015-07-28       Impact factor: 25.083

Review 8.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

9.  An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.

Authors:  Yotam Drier; Matthew J Cotton; Kaylyn E Williamson; Shawn M Gillespie; Russell J H Ryan; Michael J Kluk; Christopher D Carey; Scott J Rodig; Lynette M Sholl; Amir H Afrogheh; William C Faquin; Lurdes Queimado; Jun Qi; Michael J Wick; Adel K El-Naggar; James E Bradner; Christopher A Moskaluk; Jon C Aster; Birgit Knoechel; Bradley E Bernstein
Journal:  Nat Genet       Date:  2016-02-01       Impact factor: 38.330

10.  Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity.

Authors:  Wen Fong Ooi; Manjie Xing; Chang Xu; Xiaosai Yao; Muhammad Khairul Ramlee; Mei Chee Lim; Fan Cao; Kevin Lim; Deepak Babu; Lai-Fong Poon; Joyce Lin Suling; Aditi Qamra; Astrid Irwanto; James Qu Zhengzhong; Tannistha Nandi; Ai Ping Lee-Lim; Yang Sun Chan; Su Ting Tay; Ming Hui Lee; James O J Davies; Wai Keong Wong; Khee Chee Soo; Weng Hoong Chan; Hock Soo Ong; Pierce Chow; Chow Yin Wong; Sun Young Rha; Jianjun Liu; Axel M Hillmer; Jim R Hughes; Steve Rozen; Bin Tean Teh; Melissa Jane Fullwood; Shang Li; Patrick Tan
Journal:  Nat Commun       Date:  2016-09-28       Impact factor: 14.919

View more
  87 in total

1.  Estrogen receptor α (ERα)-binding super-enhancers drive key mediators that control uterine estrogen responses in mice.

Authors:  Sylvia C Hewitt; Sara A Grimm; San-Pin Wu; Francesco J DeMayo; Kenneth S Korach
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

Review 2.  Super-enhancer function and its application in cancer targeted therapy.

Authors:  Faqing Tang; Zongbei Yang; Yuan Tan; Yuejin Li
Journal:  NPJ Precis Oncol       Date:  2020-02-12

Review 3.  Estrogen Receptors: New Directions in the New Millennium.

Authors:  Sylvia C Hewitt; Kenneth S Korach
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

4.  Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.

Authors:  Yang Gao; Tinghu Zhang; Hideki Terai; Scott B Ficarro; Nicholas Kwiatkowski; Ming-Feng Hao; Bandana Sharma; Camilla L Christensen; Edmond Chipumuro; Kwok-Kin Wong; Jarrod A Marto; Peter S Hammerman; Nathanael S Gray; Rani E George
Journal:  Cell Chem Biol       Date:  2017-12-21       Impact factor: 8.116

Review 5.  The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.

Authors:  Olga Lancho; Daniel Herranz
Journal:  Trends Cancer       Date:  2018-11-02

6.  Oncogenic HOXB8 is driven by MYC-regulated super-enhancer and potentiates colorectal cancer invasiveness via BACH1.

Authors:  Ying Ying; Yejun Wang; Xiaoyan Huang; Yanmei Sun; Junbao Zhang; Meiqi Li; Junhui Zeng; Maolin Wang; Wenjun Xiao; Lan Zhong; Bo Xu; Lili Li; Qian Tao; Xiaomei Wang; Xing-Sheng Shu
Journal:  Oncogene       Date:  2019-10-07       Impact factor: 9.867

7.  Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.

Authors:  Abdel Nasser Hosein; Huocong Huang; Zhaoning Wang; Kamalpreet Parmar; Wenting Du; Jonathan Huang; Anirban Maitra; Eric Olson; Udit Verma; Rolf A Brekken
Journal:  JCI Insight       Date:  2019-07-23

8.  Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.

Authors:  Zeyun Mi; Yandong Song; Xinyi Cao; Yi Lu; Zhiheng Liu; Xu Zhu; Meijuan Geng; Yongzhan Sun; Bingxue Lan; Chaoran He; Hui Xiong; Lirong Zhang; Yupeng Chen
Journal:  Nat Metab       Date:  2020-07-13

Review 9.  Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Leonidas Benetatos; George Vartholomatos
Journal:  Cell Mol Life Sci       Date:  2018-02-26       Impact factor: 9.261

10.  FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.

Authors:  Xiaoyong Fu; Resel Pereira; Carmine De Angelis; Jamunarani Veeraraghavan; Sarmistha Nanda; Lanfang Qin; Maria L Cataldo; Vidyalakshmi Sethunath; Sepideh Mehravaran; Carolina Gutierrez; Gary C Chamness; Qin Feng; Bert W O'Malley; Pier Selenica; Britta Weigelt; Jorge S Reis-Filho; Ofir Cohen; Nikhil Wagle; Agostina Nardone; Rinath Jeselsohn; Myles Brown; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.